12:00 AM
 | 
Aug 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Proemend: Phase III started

Ono disclosed in its 1Q12 earnings ending June 30 that it began an open-label, Japanese Phase III trial to evaluate IV Proemend fosaprepitant dimeglumine in 24 pediatric patients with malignant tumors who are scheduled to receive chemotherapy including cisplatin, cyclophosphamide or carboplatin. Patients >=12 years old will receive...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >